c/retatrutide · created 6 Sep 2023
Triple agonist. Phase 3 data, research-grade material, and a lot of unknowns.
Jastreboff et al., N Engl J Med , 2023. Phase 2. Forty-eight weeks. Mean change −24.2% in the highest dose arm. Every one of those qualifiers gets dropped when the…
Genuinely asking, not being difficult. Everyone in c/newbiequestions repeats that dose escalation is important. I believe it, but I have never seen anyone show why, and…
Trying to settle this properly because the thread from last year went in circles. The claim: glucagon matters. The counter-claim: it is measurement error. Both sides…
Right, the triple agonist question again, but with numbers this time. I have 17 data points over 12 weeks. The pattern is consistent enough that I do not think it is…
Reference standards, analytical reagents and system-suitability material. If you are running your own method, start with a known.
Reference standardsWeek 23 update. 4kg down from the start, muscle cramps basically gone since about week 63. Things that worked: consistency, protein at breakfast, walking more than I…
Right, the triple agonist question again, but with numbers this time. I have 24 data points over 24 weeks. The pattern is consistent enough that I do not think it is…
Retatrutide: GIP/GLP-1/glucagon triple agonism, the TRIUMPH programme, and the fact that most people discussing it are handling research-grade material with no human-use approval anywhere. Dose-response, heart-rate signal, and the unusually steep phase-2 weight curves get argued about here weekly.
Certified reference materials for peptide identity and purity work.
sigmaaldrich.comSeveral compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.
Reference